Ifosfamide in the treatment of small cell lung cancer.
Ifosfamide as a single agent has produced overall response rates greater than 5O% in the treatment of small cell lung cancer (SCLC). Etoposide/ifosfamide/cisplatin (VIP) has produced overall response rates of 74% to 100% with complete response rates of 27% to 64% in SCLC patients. In a Hoosier Oncology Group randomized study involving extensive-disease SCLC patients, VIP was superior to etoposide/cisplatin with regard to median time to progression (6.6 v 5.8 months), median survival times (9.1 v 7.3 months), and 2- and 3-year survival rates (13% v 5% and 5% v 0%, respectively). In limited-disease SCLC, ifosfamide/carboplatin/etoposide (ICE) achieved overall response rates of 76% to 94%, median durations of survival ranging from 14 to 19 months, and 2-year survival rates of 24% to 37%; in extensive disease, overall response rates ranged from 72% to 100%, median durations of survival ranged from 9 to 14 months, and 2-year survival rates ranged from 14% to 22%. The use of high-dose ICE plus epirubicin and peripheral blood stem cell support appears promising in the treatment of limited-disease SCLC.
Ettinger
D S
DS
The Johns Hopkins Oncology Center, Baltimore, MD 21287-8936, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D015996:Survival Rate
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide